Search Results: Treatment + Breast Cancer (18 results)

This study is testing a new targeted therapy, sacituzumab tirumotecan, given alone or with the immunotherapy Keytruda (pembrolizumab) to treat triple-negative, metastatic breast cancer (TNBC). Keytruda is an immunotherapy that is FDA approved to treat TNBC. The goal of the study is to learn how well sacituzumab tirumotecan can cause tumors to shrink or disappear and how long that response lasts.

This trial will study the safety, tolerability, and initial effectiveness of MOMA-313, a new type of targeted therapy, alone or in combination with the PARP inhibitor olaparib to treat people with advanced or metastatic cancers with certain types of mutations.

The study will test if an investigational treatment, XL309, is safe and works when used alone or in combination with a PARP inhibitor to treat people with some advanced solid tumors. The study is enrolling people with BRCA1 or BRCA2 inherited mutations and have HER2-negative breast cancer, prostate cancer, pancreatic cancer, high grade ovarian, fallopian tube or primary peritoneal cancer; or other solid tumors with certain genetic mutations. 

EvoPAR-BR01 is studying two investigational drugs as first-line treatment for HER2-negative, HR-positive, metastatic breast cancer in people with an inherited or tumor mutation in BRCA1, BRCA2 or PALB2. Saruparib is a new PARP1 inhibitor (a type of targeted therapy). Camizestrant is an estrogen receptor degrader (a type of hormonal therapy). The study will look at different combinations of treatments to learn which combination leads to the best survival and fewest side effects. 

The goal of this treatment study is to learn if the new drug GS-0201 is safe and can help treat people with different types of metastatic or advanced cancer. GS-0201 is a new drug that has not yet been approved for treatment of cancer. GS-0201 is a type of targeted therapy known as a PARP1 inhibitor. 

This clinical trial is studying a new combination of drugs to treat metastatic, HER2-negative or HER2-low breast cancer in people with an inherited mutation in BRCA1, BRCA2 or PALB2 or a tumor mutation in BRCA1 or BRCA2. The study is looking at whether adding a new targeted therapy drug called axatilimab to treatment with the PARP inhibitor olaparib (Lynparza) will improve outcomes in people with metastatic breast cancer. 

This is a study looking at biomarkers to predict recurrence in people with high-risk, early-stage breast cancer who are planning to undergo chemotherapy. This study will follow patients forward over a period of time to see how well the test cancer predict outcomes.

The study is designed to find the safest dose of a drug called TNG260, given along with a standard dose of the immunotherapy drug pembrolizumab, in people with advanced or metastatic solid tumors and have a STK11 genetic mutation.

This study is testing whether a shorter course of combined chemotherapy and immunotherapy treatment—without a type of chemotherapy known as an anthracycline—works as well as the standard, longer treatment for people with early-stage triple-negative breast cancer at high risk for recurrence.

This study is for people with advanced or metastatic breast cancer, have a BRCA1 or BRCA2 genetic mutation and were previously treated with a PARP inhibitor. The study will examine how effective  Olaparib in combination with Cediranib or Ceralasertib is in reducing the size of cancer and determining the length of time patients respond well to the treatment.

This study is looking at the safety and best dose for treatment with the drug ONM-501 alone or in combination with immunotherapy for treating advanced solid tumors or lymphomas. 

This research involves studying a drug called AZD9574 on its own and in combination with other anti-cancer drugs in people with advanced cancer that has come back or progressed. AZD9574 is a type of targeted therapy known as a PARP inhibitor. The study aims to understand the safety, tolerance, how the drug moves in the body, how it affects the body, and its initial effectiveness.

This study will compare robotic-assisted nipple sparing mastectomy (NSM) to standard surgery NSM for women with early-stage breast cancer. Eligible women will be randomly placed into one of two groups and either undergo the robotic-assisted procedure or undergo the standard of care open surgery for NSM. Participants will be followed for 5 years.

The TAPUR Study aims to describe the safety and efficacy of Food and Drug Administration (FDA)-approved, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic alteration.

This study is looking whether the drug Talazoparib (also known as Talzenna) is safe and effective for treating people with advanced solid cancers (including breast, gastric, ovarian, pancreatic, prostate or other solid tumors) in people with an inherited mutation (found through genetic testing) or an acquired mutation (found with biomarker testing) in ATM, ATR, BRCA1, BRCA2, BRIP1, BAP1, BARD1, CDK12, CHEK1, CHEK2, IDH1, IDH2, MRE11A, NBN, PALB2, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAD54L or other genes.

The purpose of this study is to see whether the combination of melphalan, BCNU, hydroxocobalamin, ascorbic acid, and autologous (self) bone marrow stem cell infusion, is safe and effective for treating patients with advanced pancreatic cancer or Stage IV, HER2-negative breast cancer who have a BRCA1, BRCA2 or PALB2 inherited mutation. All of these treatments are given intravenously (by vein). This study is open to people who have already received a PARP inhibitor, as well as those who have not. There are no restrictions on the number of prior treatments a patient has received before enrolling.

This study will look at how well a new oral targeted therapy known as an ATR inhibitor works on advanced or metastatic solid tumors with mutations in genes linked to DNA damage repair. The study will look at response to treatment with the drug ART0380 in combination with the chemotherapy agent, gemcitabine. 

This is a study for patients with metastatic breast cancer who do not have an inherited mutation in BRCA1 or BRCA2 but who are are found to have a BRCA1 or BRCA2 acquired tumor mutation (somatic mutation) found through liquid biopsy. Patients are treated with talazoparib, a well-tolerated oral PARP inhibitor that targets the BRCA1and BRCA2 mutation to determine whether this treatment (which is already approved for germline BRCA1 and BRCA2 carriers) is effective in this population.